Design Therapeutics (NASDAQ:DSGN) Price Target Raised to $14.00

Design Therapeutics (NASDAQ:DSGN) had its price objective hoisted by Royal Bank Of Canada from $13.00 to $14.00 in a report issued on Tuesday,Benzinga reports. Royal Bank Of Canada currently has an outperform rating on the stock.

DSGN has been the subject of several other reports. Wall Street Zen upgraded Design Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, February 14th. Leerink Partners set a $14.00 target price on Design Therapeutics and gave the company an “outperform” rating in a research note on Wednesday, December 3rd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Design Therapeutics in a research report on Wednesday, January 21st. Craig Hallum initiated coverage on Design Therapeutics in a research note on Wednesday, December 3rd. They set a “buy” rating and a $15.00 price target for the company. Finally, Oppenheimer assumed coverage on Design Therapeutics in a research note on Wednesday, January 7th. They issued an “outperform” rating and a $18.00 price target for the company. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $15.25.

Design Therapeutics Stock Performance

Design Therapeutics stock opened at $10.02 on Tuesday. Design Therapeutics has a twelve month low of $2.60 and a twelve month high of $11.14. The firm has a market cap of $617.93 million, a PE ratio of -8.21 and a beta of 1.63. The firm’s 50 day moving average price is $10.00 and its two-hundred day moving average price is $8.29.

Design Therapeutics (NASDAQ:DSGN) last issued its earnings results on Monday, March 9th. The company reported ($0.27) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.38) by $0.11. Equities analysts anticipate that Design Therapeutics will post -0.91 EPS for the current fiscal year.

Institutional Investors Weigh In On Design Therapeutics

A number of large investors have recently bought and sold shares of DSGN. Woodline Partners LP acquired a new position in Design Therapeutics during the first quarter worth $2,492,000. Jane Street Group LLC bought a new stake in shares of Design Therapeutics during the 1st quarter worth about $70,000. Strs Ohio bought a new stake in shares of Design Therapeutics during the 1st quarter worth about $87,000. Los Angeles Capital Management LLC acquired a new position in shares of Design Therapeutics during the 2nd quarter valued at about $43,000. Finally, Geode Capital Management LLC increased its holdings in shares of Design Therapeutics by 2.4% during the 2nd quarter. Geode Capital Management LLC now owns 794,008 shares of the company’s stock valued at $2,676,000 after acquiring an additional 18,511 shares during the last quarter. 56.64% of the stock is currently owned by institutional investors.

Design Therapeutics Company Profile

Design Therapeutics, Inc a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders.